Objective. To explore the role of leonurine in the regulation of synovial inflammation and joint destruction inRA.
Introduction
RA is a common chronic inflammatory joint disease that is characterized by synovial hyperplasia and erosion of bone and cartilage [1] . Increasing evidence indicates that activated RA fibroblast-like synoviocytes (FLSs) exhibit tumour-like characteristics [2, 3] and play a critical role in the development of the pannus by migrating into cartilage and bone [47] . Targeting proliferative fibroblasts could facilitate the regeneration of synovial joints [8] . RA FLSs also regulate the secretion of inflammatory mediators and expression of MMP, which cause damage to cartilage and bone [9, 10] . Regulation of activated FLS-mediated inflammation and invasion may be a novel therapeutic strategy to target the destructive progress of RA.
Leonurine is an extract separated from Leonurus cardiaca, which is a traditional herbal medicine widely used in Asian countries, particularly India and China [11] . L. cardiaca shows therapeutic benefits for the treatment of internal disorders, such as cardiovascular disorders, amenorrhoea and skin inflammation [12] . Recent studies have shown the inhibitory effects of leonurine on inflammation and immunomodulation. Leonurine downregulated the pro-inflammatory cytokine levels in an LPS-induced mouse mastitis model by regulating the mitogen-activated protein kinases (MAPKs) [13] . Leonurine also reduced LPS-induced inflammatory responses in human umbilical vein endothelial cells via inhibition of reactive oxygen species and the nuclear factor kappa B (NF-kB) signalling pathway [14, 15] . However, the therapeutic benefits of leonurine in RA are unknown. Therefore, in the present study, we evaluated the role of leonurine in the regulation of synovial inflammation and joint destruction in RA and its underlying mechanisms. Our data showed that leonurine decreased pro-inflammatory cytokine and MMP production and the migration and invasion of RA FLSs by regulating the MAPK and NF-kB pathways. We also demonstrated that leonurine attenuated the severity of arthritis in mice with CIA. These results indicate that leonurine may possess therapeutic potential for RA.
Methods

Reagents and antibodies
Recombinant human TNFa was obtained from R&D Systems (Minneapolis, MN, USA). DMEM/F12, fetal bovine serum (FBS), antibiotics, PBS, trypsin-EDTA and other standard cell culture products were purchased from Invitrogen (Carlsbad, CA, USA). Leonurine and an anti-b-actin antibody were obtained from Sigma-Aldrich (St Louis, MO, USA). Anti-p38, anti-phospho-p38, anti-c-Jun N-terminal kinase (JNK), anti-phospho-JNK, anti-extracellular signalregulated kinase (ERK), anti-phospho-ERK, anti-NF-kB, anti-phospho-NF-kB, anti-inhibitor of NF-kB alpha (IkBa), anti-phospho-IkBa, anti-inhibitor of nuclear factor kappa B kinase (IKK) and anti-phospho-IKK antibodies were obtained from Cell Signaling Technology (Beverly, MA, USA). IL-1b, IL-6, IL-8, TNFa, MMP-1 and MMP-3 multiplex bead arrays were purchased from Bio-Rad (Hercules, CA, USA). SB203580, SP600125, pyrrolidinedithiocarbamate (PDTC) were purchased from Selleck (Houston, TX, USA).
Patients and controls
Twelve patients with RA (10 women and 2 men, aged 4263 years) who had undergone synovectomy or joint replacement were enrolled in this study. RA was diagnosed according to the 1987 revised criteria of the ACR [16] . This study was approved by the Medical Ethical Committee of the First Affiliated Hospital, Guangzhou University of Chinese Medicine and was performed according to the recommendations of the Declaration of Helsinki. All patients gave informed consent before participating in the study.
Cell culture
Synovial tissues were cut into small pieces and digested with collagenase in DMEM/F12 medium for 2 h at 37 C to isolate synoviocytes. The synoviocytes were cultured in DMEM/F12 medium containing 10% FBS, 100 U/ml penicillin and 100 mg/ml streptomycin at 37 C in an incubator with 5% CO 2 . These cells were used for all experiments. The cells were trypsinized at confluence and used between passages 3 and 5.
Cytokine assay
Total RNA was extracted using the TRIzol reagent (Invitrogen). The RNA was reverse-transcribed with the TaKaRa PrimeScript RT reagent kit according to the manufacturer's protocol (TaKaRa Bio, Shiga, Japan). Quantitative real-time PCR was performed using the Bio-Rad CFX96 system with the SYBR Green PCR Master Mix (Toyobo, Osaka, Japan) according to the manufacturer's instructions. The instrument was programmed with the following PCR conditions: 40 cycles of a 5 s denaturation at 95 C and a 34 s amplification at 60 C. All reactions were run in triplicate and were normalized to the housekeeping gene GAPDH. The RT-PCR primers used in this study are listed in supplementary Table  S1 , available at Rheumatology Online.
The cytokine concentrations in the supernatant samples were quantitatively determined with the Human cytometric bead array (CBA) kit according to the instructions of the BD TM CBA Flex Set System (BD Biosciences, San Jose, CA, USA). Each BD CBA Flex Set contained one bead population with a distinct fluorescence intensity as well as the appropriate phycoerythrin detection reagent and standard. The tests were performed according to the manufacturer's recommendations, and samples were run in duplicate. The MMP (MMP-1 and MMP-3) concentrations in the supernatants were detected by ELISA according to the manufacturer's instructions (R&D Systems, Minneapolis, MN, USA).
Cytotoxicity assay RA FLSs were pre-treated for 48 h with leonurine at different concentrations (0, 5, 10 or 20 mM). The culture supernatants were removed, and the adherent cells were incubated for 30 min at 37 C with a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) salt solution (1 mg/ ml in PBS). The dark blue formazan crystals were dissolved in acidified isopropanol, and formazan quantification was performed at a test wavelength of 570 nm and a reference wavelength of 620 nm.
FLS proliferation assays RA FLSs were cultured for 24 h at a density of 1 Â 10 4 cells/ well in 96-well plates in serum-free medium. After serum starvation, the cells were incubated with TNFa (10 ng/ml) for 72 h and then with 10 mM 5-bromo-2 0 -deoxyuridine (BrdU) for 1 h. BrdU incorporation was assessed in triplicate using a cell proliferation ELISA kit (Roche, Mannheim, Germany) according to the manufacturer's instructions.
FLS apoptosis assays
RA FLSs were pre-treated with leonurine at different concentrations (0, 5, 10 or 20 mM) for 48 h. Then, the apoptosis of RA FLSs was analysed by staining the cells with annexin VFITC and propidium iodide according to the manufacturer's protocol (BD Biosciences).
Wound migration RA FLSs were plated to confluence in 35-mm culture dishes, wounded with pipette tips and then treated with various concentrations of leonurine (0, 5, 10 or 20 mM). After 48 h of incubation, migration was quantified by counting the cells that had moved beyond the reference line.
In vitro migration and invasion assays
The FLS chemotaxis assay was performed using the Boyden chamber method and a 6.5-mm-diameter filter with an 8.0-mm pore size (Corning Inc., Corning, NY, USA). The RA FLSs were pre-treated with leonurine at various concentrations (0, 5, 10 or 20 mM) for 24 h and then seeded into a Boyden chamber at a final concentration of 6 Â 10 4 cells/ml. Serum-free DMEM/F12 was added to the upper chambers, and DMEM/F12 containing 10% FBS was added as a chemoattractant in the lower wells. The chamber was incubated at 37 C in the presence of 5% CO 2 for 24 h. After incubation, the nonmigrating cells were removed from the upper surface of the filter using a cotton swab. The filters were fixed in methanol for 15 min and stained with 0.1% crystal violet for 15 min. Chemotaxis was quantified by counting the stained cells that migrated to the lower side of the filter using an optical microscope. The stained cells were counted as the mean number of cells per 10 random fields for each assay. For the in vitro invasion assay, similar experiments were performed using inserts coated with a Matrigel basement membrane matrix (BD Biosciences).
IF staining
RA FLSs were grown on glass coverslips to 90% confluence. A sterilized pipette tip was used to generate wounds across the cell monolayer, which was washed three times with starvation medium to remove the detached cells. RA FLSs were pre-treated with 1% (v/v) dimethyl sulfoxide (DMSO) or leonurine (20 mM) for 24 h, stimulated with or without TNFa for 30 min, fixed with 4% paraformaldehyde and then permeated with 0.1% Triton X-100 in PBS. The cells were incubated with an anti-p65 NF-kB antibody (diluted 1:200) for 1 h at room temperature and then with an FITC-conjugated secondary Ab (Santa Cruz Biotechnology, Dallas, TX, USA). To detect the pseudopodia organization, the cells were incubated with Alexa Fluor-546 rhodamine-phalloidin (Invitrogen, Eugene, OR, USA), and the nuclei were visualized using 0.25 mg/ml 4 0 ,6-diamidino-2-phenylindole. The coverslips were mounted onto glass slides with anti-fade mounting medium and examined using fluorescence microscopy.
Western blotting analysis
For each experiment, a total of 5 Â 10 5 cells were seeded;
when subconfluence (70%) was reached, the cells were made quiescent for 24 h in DMEM/F12 medium containing 0.5% FBS and then treated with various agents. To detect the expression of signal proteins, we rinsed the cells twice with ice-cold PBS and added 0.5 ml of ice-cold lysis buffer [50 mM TrisHCl, pH 7.5, 150 mM NaCl, 100 mg/ml phenylmethylsulfonyl fluoride, 0.1% SDS, 1% Nonidet P-40 (NP-40), 0.5% sodium deoxycholate, 10 mg/ml aprotinin, 2 mg/ml leupeptin and 10 mM EDTA]. The cells were incubated for 20 min on ice and then scraped and centrifuged. The protein concentrations were measured using the Bicinchoninic Acid Protein Assay Kit (Pierce, Rockford, IL, USA). Equal amounts of protein were solubilized in Laemmli buffer (62.5 mM TrisHCl, pH 6.8, 10% glycerol, 2% SDS, 5% b-mercaptoethanol and 0.00625% bromophenol blue), boiled for 5 min, separated by SDSPAGE and transferred to nitrocellulose membranes. The membranes were probed with primary Abs as indicated in Trisbuffered salineTween 20 containing 5% non-fat milk at 4 C overnight. The membranes were incubated with the appropriate secondary Abs for 1 h at room temperature. Immunoreactive bands were visualized using enhanced chemiluminescence (Amersham Pharmacia, Piscataway, NJ, USA). Each blot was representative of at least three similar independent experiments.
Determination of the effect of leonurine on CIA CIA was induced in DBA1 mice by intradermal injection of 200 mg of bovine type II collagen emulsified at a 1:1 ratio (v/v) in Freund's complete adjuvant. The mice were boosted 3 weeks later using bovine type II collagen emulsified at a 1:1 ratio (v/v) in incomplete Freund's adjuvant. Two groups (n = 8 mice each) were treated with once-daily intraperitoneal injections of either DMSO (vehicle) or leonurine (30 mg/kg/day) for 14 days beginning on the day of arthritis onset. The arthritis severity was graded on a scale of 04 for each paw in a blinded fashion as follows: 0, no change; 1, significant swelling and redness of one digit; 2, mild swelling and erythema of the limb or swelling of more than two digits; 3, marked swelling and erythema of the limb; and 4, maximal swelling and redness of the limb followed by ankylosis. The total score was recorded as the sum of the scores in the four limbs. After 14 days of treatment, the hind limbs were removed and fixed in 10% neutral buffered formalin. The tissue was decalcified in 8% formic acid and embedded in paraffin. The sections were stained with haematoxylin and eosin. An inflammation, hyperplasia, bone damage score was obtained using the following scoring system: 0, normal; 1, mild; 3, moderate; and 4, severe.
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To determine the toxic effect of leonurine on mice with CIA, a colorimetric enzymatic method was used for the biochemical analysis of serum samples. The enzymatic activities of aspartate aminotransferase and alanine aminotransferase were detected to investigate liver function alterations. Serum creatinine and blood urea nitrogen (BUN) were detected as renal parameters. These parameters were analysed using commercial kits (Jiancheng Bioengineering Institute, Nanjing, China) according to the manufacturer's instructions.
Measurement of serum cytokine production in mice Mouse plasma was obtained by centrifugation of blood in serum separator Microtainer tubes after cardiac puncture. The serum levels of pro-inflammatory cytokines (IL-1b, IL-6 and TNFa) in the mice were examined by ELISA according to the manufacturer's instructions (R&D Systems).
Statistical analysis
The data are expressed as the mean (S.E.M.). Analysis of variance with the StudentNewmanKeuls test was used to evaluate differences between the experimental groups. The histological results were analysed using the KruskalWallis non-parametric test. P < 0.05 was considered significant.
Results
Inhibitory effect of leonurine on the TNFa-induced pro-inflammatory cytokine and MMP production by RA FLSs Pro-inflammatory cytokines and MMPs play important roles in synovial inflammation and joint destruction. As shown in Fig. 1A and B, the IL-1b, IL-6, IL-8, TNFa, MMP-1 and MMP-3 mRNA and protein expression levels in TNFa-induced RA FLSs were decreased by leonurine treatment at concentrations ranging from 5 to 20 mM.
Effects of leonurine on RA FLS viability
The MTT assay was performed to evaluate the toxic effects of leonurine on RA FLSs. As shown in Fig. 1C , the RA FLSs were incubated with varying concentrations (0, 5, 10 or 20 mM) of leonurine for 48 h. Based on these results, leonurine did not affect cell viability, even at concentrations as high as 20 mM.
Effects of leonurine on the proliferation and apoptosis of RA FLSs A previous report indicated that leonurine participated in the regulation of tumour cell proliferation and apoptosis [17] . Therefore, we examined the role of leonurine in the proliferation and apoptosis of RA FLSs. Our results showed that leonurine was not involved in the proliferation or apoptosis of RA FLSs (Fig. 1D and E) .
Inhibitory effect of leonurine on the migration and invasion of RA FLSs
To determine the role of leonurine in RA FLS migration, we examined the chemotactic migration of FLSs using a Boyden chamber assay. As shown in Fig. 2A , leonurine treatment markedly suppressed the migratory capacity of RA FLSs in a concentration-dependent manner. To evaluate the effect of leonurine on FLS migration, we used a monolayer wound scratch assay. Consistent with previous results, leonurine treatment resulted in a significant reduction in cell migration (Fig. 2B) .
The ability to invade cartilage is a critical behaviour in RA pathogenesis. The in vitro invasion potential of RA FLSs is related to the rate of joint destruction in RA patients [18] . A thin layer of reconstituted extracellular matrix (Matrigel) was used to evaluate the role of leonurine in the invasive behaviour of RA FLSs in vitro. As shown in Fig. 2C , leonurine treatment caused a significant reduction in RA FLS invasiveness.
Leonurine impairs lamellipodia formation in RA FLSs
Dynamic reorganization of the actin cytoskeleton is critical for optimal cell migration. To confirm the role of leonurine in the regulation of actin reorganization in RA FLSs, we used fluorescent phalloidin staining to visualize polymerized actin in leonurine (20 mM) or 1% (v/v) DMSO-treated migrating cells shortly after wounding. As shown in Fig. 2D , the FLSs in the DMSO group displayed flat or ruffling lamellipodia at their leading edge, whereas the cells treated with leonurine exhibited significantly suppressed lamellipodia formation.
Inhibitory effect of leonurine on NF-kB activation by TNFa-induced RA FLSs NF-kB plays a critical role in regulating the production of synovial inflammation and joint destruction. Therefore, we evaluated the effect of leonurine on NF-kB activation. We found a significant decrease in phosphorylated NFkB and IkBa following treatment of TNFa-stimulated RA FLSs with leonurine, but leonurine treatment had no effect on the expression of phosphorylated IKK (Fig.  3A) . As shown in Fig. 3B , we also performed IF staining using an anti-p65 antibody targeting a major subunit of NF-kB. We observed a significant reduction in p65 nuclear accumulation in the RA FLSs treated with leonurine.
Inhibitory effect of leonurine on the phosphorylation of MAPK pathway components in TNFa-induced RA FLSs
MAPKs also play important roles in regulating synovial inflammation and the invasion of RA FLSs. To determine the role of leonurine in the MAPK pathways, we measured the expression of candidate signalling molecules following leonurine treatment. As shown in Fig. 3C , leonurine treatment decreased the TNFa-induced phosphorylation of the phospho-JNK and p38 MAPKs but had no effect on the expression of phospho-extracellular signal regulating kinase 1/2 (ERK1/2).
Since the MAPK pathway is considered a critical upstream factor for NF-kB activation [19, 20] , we determined the effect of p38 and JNK chemical inhibitors on www.rheumatology.oxfordjournals.org NF-kB activation to evaluate whether p38 or JNK mediated the leonurine-induced inactivation of NF-kB. The p38 chemical inhibitor decreased activation of the NF-kB pathway, whereas the JNK chemical inhibitor did not affect NF-kB activation ( Fig. 3D and E) . These data suggest that p38 mediates TNFa-induced NF-kB activation in RA FLSs.
Effect of p38, JNK and NF-kB chemical inhibitors on pro-inflammatory cytokine and MMP expression and the migration and invasion of RA FLSs
We demonstrated that treatment with chemical inhibitors of p38, JNK and NF-kB reduced the TNFa-induced increase in IL-1b, IL-6, IL-8, TNFa, MMP-1 and MMP-3 expression in RA FLSs (Fig. 4A and B) . We also observed an inhibitory effect of these chemical inhibitors on the migration and invasion of RA FLSs (Fig. 4C and D) .
Attenuation of the severity of arthritis in mice with CIA via leonurine administration Given these observations in cultured RA FLSs, the in vivo effect of leonurine on the synovial inflammation of RA was evaluated in mice with CIA. Intraperitoneal injection of leonurine suppressed the increase in the clinical score compared with mice treated with DMSO (Fig. 5AC) . We also conducted histological examinations to evaluate the joint pathology in mice. The leonurine-treated mice showed a significant reduction in the pathological disease severity and a corresponding reduction in the macroscopic inflammation score compared with the DMSOtreated mice (Fig. 5D) . Additionally, we observed a significant reduction in the serum IL-1b, IL-6 and TNFa levels in the mice with CIA treated with leonurine (Fig. 5E) .
Moreover, we found no significant gain in body weight between the leonurine and DMSO groups over the course of the experiment. We found no significant changes in the liver (aspartate aminotransferase and alanine aminotransferase levels) or renal (serum creatinine and BUN levels) parameters in mice treated with leonurine (supplementary Table S2 , available at Rheumatology Online). These data indicate that leonurine treatment is safe in CIA mice.
Discussion
In the present study, we demonstrated that leonurine treatment suppressed pro-inflammatory cytokine and MMP production and the migration and invasion of RA FLSs. Leonurine also inhibited the activation of the NF-kB, p38 and JNK MAPK pathways. Intraperitoneal administration of leonurine attenuated synovial inflammation and joint destruction in mice with CIA. Our findings suggest that leonurine has potential as a novel therapeutic agent for RA. Leonurine, which is derived from Leonurus cardiaca, has been implicated in a large range of pharmacological actions [21] . Several studies have shown that it exhibits a wide range of biological activities, including analgesic [22] , anti-inflammatory [23] , anti-tumour [17] and bone protectant activities [24] . These observations suggest benefits of leonurine for the treatment of inflammatory disorders and tumours. However, whether leonurine has the potential for RA treatment is unknown. In this work, we found that leonurine downregulated not only IL-1b, IL-6, IL-8 and TNFa production but also MMP-1 and MMP-3 expression in TNFa-stimulated RA FLSs in a concentration-dependent manner, which suggested a role for leonurine in the regulation of FLS-mediated inflammation. The results from the in vivo experiments in mice with CIA further support the hypothesis that leonurine may have potential as an agent to control synovial inflammation in RA.
Increasing evidence suggests that the migration of FLSs to cartilage and bone plays a key role in cartilage destruction in RA. Once they arrive at cartilage or bone, FLSs can activate osteoclasts to enhance bone erosion and destruction [25, 26] . Thus, regulation of FLS migration may be a new therapeutic strategy for the destructive progress of RA. Therefore, we determined the effect of leonurine on the migration and invasion of RA FLSs in this study. We demonstrated that leonurine suppressed the migration and invasion of FLSs from RA patients and reduced www.rheumatology.oxfordjournals.org formation of lamellipodia, which is a critical step that controls cell migration [27, 28] . Consistent with our findings, leonurine also inhibited LPS-induced inflammatory responses in human umbilical vein endothelial cells and the proliferation of H292 in lung cancer cells [15, 23] . These findings suggest that leonurine might be beneficial for the prevention of joint destruction in RA patients.
Multiple signal transduction pathways participate in the regulation of RA pathogenesis, including NF-kB and MAPK, which are considered key signalling factors in the control of synovial inflammation and joint destruction [29, 30] . To investigate the signalling mechanisms affected by leonurine in the regulation of synovial inflammation, we evaluated the effect of leonurine on the NF-kB and MAPK pathways. In the present study, leonurine suppressed the TNFa-induced phosphorylation of IkBa and inhibited the translocation of nuclear NF-kB, indicating that leonurine regulated the NF-kB pathway through interference with the cytoplasmic IkBa signal. Consistent with our data, recent studies have shown that leonurine can regulate the activation of NF-kB in human umbilical vein endothelial cells [15] , RAW 264.7 macrophages [31] and mouse bone marrow monocytes [13] .
Recent studies have shown that leonurine inhibits MAPK pathways in TNFa-induced human umbilical vein endothelial cells and an LPS-induced mouse mastitis model [13, 14] . In this work, leonurine inhibited TNFainduced p38 and JNK phosphorylation but did not affect the phosphorylation of the ERK MAPKs in RA FLSs. Furthermore, we demonstrated that chemical inhibitors of JNK, p38 and NF-kB significantly reduced proinflammatory cytokine and MMP expression and the migration and invasion of TNFa-induced RA FLSs. These data suggest that the JNK, p38 and NF-kB pathways are involved in the regulation of leonurine in TNFa-induced RA FLSs.
The MAPK pathway has been considered a crucial upstream factor for the activation of the NF-kB signalling complex [19, 20] . Several reports have indicated the involvement of MAPKs in the regulation of NF-kB activation through IkBa phosphorylation [32, 33] . In the current study, we found that the p38 chemical inhibitor exhibited inhibitory effects on IkBa phosphorylation. Taken together, our findings suggest that leonurine regulates the pathological behaviours of RA FLSs through the JNK MAPK and p38-mediated NF-kB pathways.
In summary, we demonstrate for the first time that leonurine ameliorates joint inflammation by regulating the JNK MAPK and p38-mediated NF-kB pathways. Our findings suggest that leonurine may be a potential therapeutic agent for inflammatory arthritis.
